PharmaJet Presents Needle-free Delivery of COVID-19 DNA Vaccine Results at World Vaccine Congress

Superior immunogenicity cited with Needle-free delivery

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet^®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.

The Tropis® Needle-free device is being used in multiple COVID-19 DNA vaccine development programs in partnership with Zydus Cadila, BioNet Asia, GeneOne Life Science, and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), among others. The vaccine developed by Zydus Cadila is furthest along, with Phase III clinical trials in progress. Phase I and II clinical trials were completed in January, and the Phase II results showed the ZYCOV-D COVID-19 DNA vaccine delivered with the Tropis system was safe and elicited a strong immunogenic response.¹

“The PharmaJet Needle-free injection technology has been proven safe and effective with commercial vaccines and pharmaceuticals including influenza, MMR, HPV, IPV, and others. Now being used to deliver COVID-19 vaccines, the technology continues to show robust safety and overwhelmingly positive clinical efficacy,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “An increasing amount of data is showing superior efficacy over other delivery methods with nucleic acid-based platforms for vaccines, passive antibodies, and personalized medicine.”

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/zydus-to-release-final-vax-data/articleshow/81398661.cms?from=mdr

About PharmaJet

PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis^® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® device for intradermal injections received authorization to apply the CE Mark in May 2016. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com. Follow us on LinkedIn.